Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV Jr, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, Dubinsky M, Schreiber S, Ilo D, Finney-Hayward T, Zhou W, Phillips C, Gonzalez YS, Shu L, Yao X, Zhou Q, Vermeire S. Loftus EV Jr, et al. Among authors: colombel jf. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2347-2358.e6. doi: 10.1016/j.cgh.2022.11.029. Epub 2022 Dec 1. Clin Gastroenterol Hepatol. 2023. PMID: 36464141 Free article.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. Among authors: colombel jf. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, Yao X, Chen S, Sanchez Gonzalez Y, Hébuterne X, Lindsay JO, Higgins PDR, Cao Q, Nakase H, Colombel JF, Loftus EV Jr, Panaccione R. Vermeire S, et al. Among authors: colombel jf. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9. Lancet Gastroenterol Hepatol. 2023. PMID: 37683686
The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
Verstockt B, Vermeire S, Peyrin-Biroulet L, Mosig R, Feagan BG, Colombel JF, Siegmund B, Rieder F, Schreiber S, Yarur A, Panaccione R, Dubinsky M, Lichtiger S, Cataldi F, Danese S. Verstockt B, et al. Among authors: colombel jf. J Crohns Colitis. 2023 Nov 11:jjad192. doi: 10.1093/ecco-jcc/jjad192. Online ahead of print. J Crohns Colitis. 2023. PMID: 37952114
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF, Schreiber S, D'Haens G, Rizzo J, Kligys K, Griffith J, Zambrano J, Zhou Q, Zhang Y, Kalabic J, Rieder F, Dubinsky M, Panaccione R. Colombel JF, et al. J Crohns Colitis. 2023 Dec 9:jjad206. doi: 10.1093/ecco-jcc/jjad206. Online ahead of print. J Crohns Colitis. 2023. PMID: 38069472
Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience.
Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, Click B, Steiner CA, Dulaney D, Levine J, Hassan SA, Perry C, Flomenhoft D, Ungaro RC, Berinstein EM, Sheehan J, Cohen-Mekelburg S, Regal RE, Stidham RW, Bishu S, Colombel JF, Higgins PDR. Berinstein JA, et al. Among authors: colombel jf. Am J Gastroenterol. 2024 Mar 27. doi: 10.14309/ajg.0000000000002674. Online ahead of print. Am J Gastroenterol. 2024. PMID: 38275248
1,122 results